{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:20:57Z","timestamp":1785151257919,"version":"3.55.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Persister formation of Escherichia coli under fluoroquinolone exposure causes treatment failure and promotes emergence of resistant strains. Semi-mechanistic pharmacokinetic\/pharmacodynamic modelling of data obtained from in vitro infection model experiments comprehensively characterizes exposure\u2013effect relationships, providing mechanistic insights.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To quantify persister formation of E. coli under levofloxacin exposure and to explain the observed growth-kill behaviour, leveraging electronic cell counting and pharmacokinetic\/pharmacodynamic modelling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Three fluoroquinolone-resistant clinical E. coli isolates were exposed to levofloxacin in static and dynamic in vitro infection model experiments. Complementary to plate counting, bacterial concentrations over time were quantified by electronic cell counting and amalgamated in a semi-mechanistic pharmacokinetic\/pharmacodynamic model (1281 bacterial and 394 levofloxacin observations).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Bacterial regrowth was observed under exposure to clinically relevant dosing regimens in the dynamic in vitro infection model. Electronic cell counting facilitated identification of three bacterial subpopulations: persisters, viable cells and dead cells. Two strain-specific manifestations of the levofloxacin effect were identified: a killing effect, characterized as a sigmoidal Emax model, and an additive increase in persister formation under levofloxacin exposure. Significantly different EC50 values quantitatively discerned levofloxacin potency for two isolates displaying the same MIC value: 8\u2009mg\/L [EC50\u2009=\u200917.2 (95% CI\u2009=\u200912.6\u201323.8) mg\/L and 8.46 (95% CI\u2009=\u20096.86\u201310.3) mg\/L, respectively]. Persister formation was most pronounced for the isolate with the lowest MIC value (2\u2009mg\/L).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The developed pharmacokinetic\/pharmacodynamic model adequately characterized growth-kill behaviour of three E. coli isolates and unveiled strain-specific levofloxacin potencies and persister formation. The mimicked dosing regimens did not eradicate the resistant isolates and enhanced persister formation to a strain-specific extent.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkab146","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:04:33Z","timestamp":1619093073000},"page":"2088-2096","source":"Crossref","is-referenced-by-count":10,"title":["Quantification of persister formation of<i>Escherichia coli<\/i>leveraging electronic cell counting and semi-mechanistic pharmacokinetic\/pharmacodynamic modelling"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5868-1302","authenticated-orcid":false,"given":"Johanna","family":"Seeger","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstr. 31, 12169, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-607X","authenticated-orcid":false,"given":"Robin","family":"Michelet","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstr. 31, 12169, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstr. 31, 12169, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"2021071609141076700_dkab146-B1","year":"2019","journal-title":"Surveillance of Antimicrobial Resistance in Europe 2018"},{"key":"2021071609141076700_dkab146-B2"},{"key":"2021071609141076700_dkab146-B3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of quinolone action and resistance: where do we stand?","volume":"66","author":"Correia","year":"2017","journal-title":"J Med Microbiol"},{"key":"2021071609141076700_dkab146-B4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"2021071609141076700_dkab146-B5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1054\/drup.1998.0068","article-title":"Mechanisms of fluoroquinolone resistance","volume":"2","author":"Hooper","year":"1999","journal-title":"Drug Resist Updat"},{"key":"2021071609141076700_dkab146-B6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol"},{"key":"2021071609141076700_dkab146-B7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrmicro1557","article-title":"Persister cells, dormancy and infectious disease","volume":"5","author":"Lewis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"2021071609141076700_dkab146-B8","doi-asserted-by":"crossref","first-page":"e1000760","DOI":"10.1371\/journal.pgen.1000760","article-title":"SOS response induces persistence to fluoroquinolones in Escherichia coli","volume":"5","author":"D\u00f6rr","year":"2009","journal-title":"PLoS Genet"},{"key":"2021071609141076700_dkab146-B9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41579-019-0196-3","article-title":"Definitions and guidelines for research on antibiotic persistence","volume":"17","author":"Balaban","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2021071609141076700_dkab146-B10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41467-019-09058-4","article-title":"Enhanced antibiotic resistance development from fluoroquinolone persisters after a single exposure to antibiotic","volume":"10","author":"Barrett","year":"2019","journal-title":"Nat Commun"},{"key":"2021071609141076700_dkab146-B11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/pathogens2020422","article-title":"Can we prevent antimicrobial resistance by using antimicrobials better?","volume":"2","author":"Soothill","year":"2013","journal-title":"Pathogens"},{"key":"2021071609141076700_dkab146-B12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u201cbug and drug\u201d","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2021071609141076700_dkab146-B13","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2021071609141076700_dkab146-B14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of\u03b2-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"2021071609141076700_dkab146-B15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.phrs.2018.07.005","article-title":"Clinical applications of population pharmacokinetic models of antibiotics: challenges and perspectives","volume":"134","author":"De Velde","year":"2018","journal-title":"Pharmacol Res"},{"key":"2021071609141076700_dkab146-B16","doi-asserted-by":"crossref","first-page":"106008","DOI":"10.1016\/j.ijantimicag.2020.106008","article-title":"How preclinical infection models help define antibiotic doses in the clinic","volume":"56","author":"T\u00e4ngd\u00e9n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021071609141076700_dkab146-B17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2021071609141076700_dkab146-B18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021071609141076700_dkab146-B19","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1093\/jac\/dky232","article-title":"Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021071609141076700_dkab146-B20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.48.2.369-377.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC","volume":"48","author":"Mueller","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609141076700_dkab146-B21","year":"2016"},{"key":"2021071609141076700_dkab146-B22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkp434","article-title":"In vitro pharmacodynamic models to determine the effect of antibacterial drugs","volume":"65","author":"Gloede","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2021071609141076700_dkab146-B23","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1007\/s11095-015-1632-3","article-title":"Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus","volume":"32","author":"Wicha","year":"2015","journal-title":"Pharm Res"},{"key":"2021071609141076700_dkab146-B24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-7012(00)00241-4","article-title":"How to optimize the drop plate method for enumerating bacteria","volume":"44","author":"Herigstad","year":"2001","journal-title":"J Microbiol Methods"},{"key":"2021071609141076700_dkab146-B25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0378-1097(03)00856-5","article-title":"Persister cells and tolerance to antimicrobials","volume":"230","author":"Keren","year":"2004","journal-title":"FEMS Microbiol Lett"},{"key":"2021071609141076700_dkab146-B26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.15252\/msb.20166998","article-title":"Bacterial persistence is an active \u03c3S stress response to metabolic flux limitation","volume":"12","author":"Radzikowski","year":"2016","journal-title":"Mol Syst Biol"},{"key":"2021071609141076700_dkab146-B27","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1126\/science.1099390","article-title":"Bacterial persistence as a phenotypic switch","volume":"305","author":"Balaban","year":"2004","journal-title":"Science"},{"key":"2021071609141076700_dkab146-B28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1099\/mic.0.000436","article-title":"MazEF toxin-antitoxin proteins alter Escherichia coli cell morphology and infrastructure during persister formation and regrowth","volume":"163","author":"Cho","year":"2017","journal-title":"Microbiology"},{"key":"2021071609141076700_dkab146-B29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.gene.2015.09.069","article-title":"Overexpression of SOS genes in ciprofloxacin resistant Escherichia coli mutants","volume":"576","author":"Pourahmad Jaktaji","year":"2016","journal-title":"Gene"},{"key":"2021071609141076700_dkab146-B30","doi-asserted-by":"crossref","first-page":"eaav9462","DOI":"10.1126\/sciadv.aav9462","article-title":"Single-cell imaging and characterization of Escherichia coli persister cells to ofloxacin in exponential cultures","volume":"5","author":"Goormaghtigh","year":"2019","journal-title":"Sci Adv"},{"key":"2021071609141076700_dkab146-B31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/AAC.00604-06","article-title":"Semimechanistic pharmacokinetic\/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments","volume":"51","author":"Nielsen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609141076700_dkab146-B32","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1093\/jac\/dkw205","article-title":"A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure","volume":"71","author":"Ungphakorn","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021071609141076700_dkab146-B33","doi-asserted-by":"crossref","first-page":"e02070-19","DOI":"10.1128\/AAC.02070-19","article-title":"Extension of pharmacokinetic\/pharmacodynamic (PK\/PD) time-kill studies to include LPS\/endotoxin release from E. coli exposed to cefuroxime","volume":"64","author":"Thorsted","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609141076700_dkab146-B34","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1093\/jac\/dkv233","article-title":"A mechanism-based pharmacokinetic\/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants","volume":"70","author":"Khan","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021071609141076700_dkab146-B35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1128\/am.10.5.480-485.1962","article-title":"Experiences with the Coulter counter in bacteriology","volume":"10","author":"Swanton","year":"1962","journal-title":"Appl Microbiol"},{"key":"2021071609141076700_dkab146-B36","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1128\/jb.168.3.1466-1467.1986","article-title":"Determination of bacterial cell volume with the Coulter counter","volume":"168","author":"Kubitschek","year":"1986","journal-title":"J Bacteriol"},{"key":"2021071609141076700_dkab146-B37","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1128\/jb.82.6.857-866.1961","article-title":"Cell multiplication studied with an electronic particle counter","volume":"82","author":"Toennies","year":"1961","journal-title":"J Bacteriol"},{"key":"2021071609141076700_dkab146-B38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/jcp.34.2.194","article-title":"Rapid screening for bacteriuria using a particle counter, pulse-height analyser, and computer","volume":"34","author":"Alexander","year":"1981","journal-title":"J Clin Pathol"},{"key":"2021071609141076700_dkab146-B39","year":"2018"},{"key":"2021071609141076700_dkab146-B40","author":"Goebgen","year":"2018"},{"key":"2021071609141076700_dkab146-B41","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1128\/AAC.40.11.2478","article-title":"Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model","volume":"40","author":"L\u00f6wdin","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609141076700_dkab146-B42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11095-021-02994-1","article-title":"Which analysis approach is adequate to leverage clinical microdialysis data? A quantitative comparison to investigate exposure and reponse exemplified by levofloxacin","volume":"38","author":"Busse","year":"2021","journal-title":"Pharm Res"},{"key":"2021071609141076700_dkab146-B43","year":"2018"},{"key":"2021071609141076700_dkab146-B44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","article-title":"Likelihood based approaches to handling data below the quantification limit using NONMEM VI","volume":"35","author":"Ahn","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2021071609141076700_dkab146-B45","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2021071609141076700_dkab146-B46","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Contr"},{"key":"2021071609141076700_dkab146-B47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","article-title":"Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling","volume":"43","author":"Dosne","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2021071609141076700_dkab146-B48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","article-title":"An automated sampling importance resampling procedure for estimating parameter uncertainty","volume":"44","author":"Dosne","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2021071609141076700_dkab146-B49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.rvsc.2017.01.003","article-title":"Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers","volume":"112","author":"Lee","year":"2017","journal-title":"Res Vet Sci"},{"key":"2021071609141076700_dkab146-B50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/jac\/dkl356","article-title":"Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model","volume":"58","author":"Odenholt","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021071609141076700_dkab146-B51","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.05693-11","article-title":"Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli","volume":"56","author":"Singh","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609141076700_dkab146-B52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/bs.aambs.2015.02.004","article-title":"Modulation of bacterial proliferation as a survival strategy","volume":"92","author":"Heinrich","year":"2015","journal-title":"Adv Appl Microbiol"},{"key":"2021071609141076700_dkab146-B53","doi-asserted-by":"crossref","first-page":"e01605-16","DOI":"10.1128\/AAC.01605-16","article-title":"Bacterial replication rate modulation in combination with antimicrobial therapy: turning the microbe against itself","volume":"61","author":"Ambrose","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609141076700_dkab146-B54","doi-asserted-by":"crossref","first-page":"e1000541","DOI":"10.1371\/journal.ppat.1000541","article-title":"Interplay in the selection of fluoroquinolone resistance and bacterial fitness","volume":"5","author":"Marcusson","year":"2009","journal-title":"PLoS Pathog"},{"key":"2021071609141076700_dkab146-B55","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/jac\/dkv144","article-title":"Effect of the efflux pump QepA2 combined with chromosomally mediated mechanisms on quinolone resistance and bacterial fitness in Escherichia coli","volume":"70","author":"Machuca","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/8\/2088\/39065397\/dkab146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/8\/2088\/39065397\/dkab146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T05:03:16Z","timestamp":1671944596000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/8\/2088\/6276587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,5,17]]},"published-print":{"date-parts":[[2021,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab146","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,5,17]]}}}